AI Science Tracker
EN

University of Texas MD Anderson Cancer Center

2 discoveries from 2021

Discoveries

Morphologic learning distinguishes CLL progression patterns in biopsy tissue

Source check: Source checked. Not independent scientific confirmation.

Finding: A random forest combined nuclear size, staining intensity, cell density and cell spacing to distinguish chronic lymphocytic leukemia, accelerated CLL and Richter transformation in biopsy regions. The combined model reported 82.4% region-level accuracy with patient-separated evaluation. Manual selection of informative regions and retrospective single-centre sampling limit its clinical interpretation; this does not establish autonomous patient diagnosis or treatment benefit.

Technology: Random forest

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A random forest learns diagnostic relationships among quantified cytologic and spatial tissue features.
Test and result
Patient-separated biopsy-region classification against expert-confirmed lymphoma categories, with repeated patient-level splitting.
Limitation / still unknown
Prospective diagnostic performance and clinical benefit remain unestablished; manually selected regions excluded difficult artifacts and residual disease patterns.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9526447/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Learned artifact localization supports a bounded radiotherapy-dose comparison

Source check: Source checked. Not independent scientific confirmation.

Finding: An Inception-V3 classifier localized dental artifacts in CT images. In fifteen separate head-and-neck treatment plans, its outputs guided comparisons of artifact-management choices; calculated target-coverage differences stayed below 0.25 percentage points. This is a retrospective planning result, not measured delivered-dose equivalence or evidence of safer treatment.

Technology: Inception-V3 convolutional neural network

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The learned slice classifier identifies locations used to define the compared artifact-management regions.
Test and result
Classifier development used 549 patients with patient-separated partitions. Fifteen other plans supplied comparisons of calculated dose after model-guided artifact localization.
Limitation / still unknown
One institution and planning system; no independent physical dosimetry, clinical outcomes or general treatment recommendation. Dose calculations are comparisons between modeled management scenarios.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8180493/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Indexed primary full clinical/model Methods and dosimetric Results/discussion; exact front identity/date and current primary notice metadata..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.